Long Position on INVA @ $19.20 on 1/22/2019 (Momentum)

Innoviva, Inc. (INVA) engages in the development and commercialization of bio-pharmaceuticals.

Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI).

It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. 

The Company is scheduled to report its quarterly results on February 6th. Ahead of that shares have formed a bullish "cup and handle" and are expected to move higher out of this formation.

Entry Point: $19.20

Stop Loss: $18.20

Trading Range:  $13.26 - $19.82

Target Price: $21.13

Updates

2/1/2019 12:09:51 PM

INVA closed at $16.65

Position closed on 2/1/2019 at price of $16.65 with a -13.28% loss in 10 days.

Back to Portfolio